For Quick Alerts
For Daily Alerts

Eyestem Raises USD 6.4 Million, In Series A Funding


Eyestem, a Bengaluru-based cell therapy company, has raised USD 6.4 million (Rs 51 crore) in a Series A round led by Biological E. Limited (BE), Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing investors Endiya Partners and Kotak Private Equity also participated in this round, valuing Eyestem at USD 46.4 million (Rs 371 crore) post-money, it said in a statement on Monday.

Eyestem Raises USD 6.4 Million In Series A Funding

Jogin Desai, Founder and Chief Executive Officer of Eyestem, said: "Post this funding, we will remain focused on solidifying our cell therapy platform and moving our flagship product for Dry AMD through early clinical trials of an international standard." "Eyecyte-RPE, the company's patented flagship product, is an experimental treatment for Dry Age-Related Macular Degeneration (Dry AMD) and the company has other products in the pipeline for the treatment of incurable diseases affecting humanity," the statement added.


Read more about: funding usd raises investors
Story first published: Monday, August 8, 2022, 12:31 [IST]
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X